Miyamoto Masaki, Haruma Ken, Kuwabara Masao, Nagano Makoto, Okamoto Takeshi, Tanaka Mio
Department of General Internal Medicine, Prefectural Hiroshima Hospital, Hiroshima, Japan.
J Gastroenterol Hepatol. 2008 Mar;23(3):393-7. doi: 10.1111/j.1440-1746.2007.05043.x. Epub 2007 Jul 1.
We conducted a community-based study to assess the incidence of newly-developed gastroesophageal reflux disease (GERD). We also analyzed the risk factors of GERD occurrence.
A total of 322 patients without acid suppression therapy (135 men, mean age: 59.8 years), who lived in the Japanese community, took a QUEST questionnaire (a self-administered questionnaire for the screening of GERD) in 1998. Blood samples were taken for the measurement of an anti-Helicobacter pylori antibody and pepsinogen (PG) I/II to assess the grade of gastric atrophy. Of these patients, 289 scored less than six points and were diagnosed as non-GERD. Two-hundred-and-forty-one patients (95 men, mean age: 67.0 years) took the QUEST questionnaire again in 2004 (after 6 years). The incidence of newly-developed GERD was analyzed. These patients were categorized into three groups based on their initial PG I/II (group A: less than three, group B: three to six, and group C: more than six). The risk factors of GERD occurrence were evaluated.
Of the 241 non-GERD patients, 37 patients (15.4%) developed GERD after 6 years. The incidence of newly-developed GERD in group C was significantly higher than both groups A and B (group A: 3.8% [three of 79], group B: 11.8% (11/93), group C: 33.3% (26/69), P < 0.01, respectively). The prevalence of H. pylori negativity, constipation, and medication of Ca antagonists in newly-developed GERD were significantly higher than in those who did not develop GERD. [Correction added after online publication on 1 July 2007: the preceding sentence has replaced one that read 'The prevalence of H. pylori negativity, constipation, and medication of Ca antagonists in newly-developed GERD were significantly higher than in those who did develop GERD.']
The incidence of newly-developed GERD in the Japanese community was 16.5% for 6 years. The incidence of newly-developed GERD patients who scored a PG I/II over six was significantly higher than those who scored lower. H. pylori negativity, constipation, and medication of Ca antagonists might be risk factors of GERD occurrence.
我们开展了一项基于社区的研究,以评估新发生的胃食管反流病(GERD)的发病率。我们还分析了GERD发生的危险因素。
共有322例未接受抑酸治疗的患者(135例男性,平均年龄:59.8岁)居住在日本社区,于1998年填写了QUEST问卷(一份用于GERD筛查的自填式问卷)。采集血样检测抗幽门螺杆菌抗体和胃蛋白酶原(PG)I/II,以评估胃萎缩程度。其中,289例患者得分低于6分,被诊断为非GERD。241例患者(95例男性,平均年龄:67.0岁)于2004年(6年后)再次填写QUEST问卷。分析新发生GERD的发病率。这些患者根据其初始PG I/II分为三组(A组:低于3,B组:3至6,C组:高于6)。评估GERD发生的危险因素。
在241例非GERD患者中,37例(15.4%)在6年后发生了GERD。C组新发生GERD的发病率显著高于A组和B组(A组:3.8%[79例中的3例],B组:11.8%(11/93),C组:33.3%(26/69),P均<0.01)。新发生GERD患者中幽门螺杆菌阴性、便秘和使用钙拮抗剂的比例显著高于未发生GERD的患者。[2007年7月1日在线发表后添加的更正:前一句已替换了原句“新发生GERD患者中幽门螺杆菌阴性、便秘和使用钙拮抗剂的比例显著高于确实发生GERD的患者。”]
日本社区新发生GERD的发病率在6年中为16.5%。PG I/II得分高于6的新发生GERD患者的发病率显著高于得分较低的患者。幽门螺杆菌阴性、便秘和使用钙拮抗剂可能是GERD发生 的危险因素。